# EDGAR Filing Document

**Accession Number:** 0001855129
**File Stem:** 0001140361-25-037846
**Filing Date:** 2025-10
**Character Count:** 3428
**Document Hash:** b711ae5b71f5c9c25a12bd553e8a92ef
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-037846.hdr.sgml**: 20251010

**ACCESSION NUMBER**: 0001140361-25-037846

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20251010

**FILED AS OF DATE**: 20251010

**DATE AS OF CHANGE**: 20251010

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GH Research PLC
- **CENTRAL INDEX KEY:** 0001855129
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40530
- **FILM NUMBER:** 251386268

**BUSINESS ADDRESS:**
- **STREET 1:** JOSHUA DAWSON HOUSE
- **STREET 2:** DAWSON STREET
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 RY95
- **BUSINESS PHONE:** 353 1 437 8334

**MAIL ADDRESS:**
- **STREET 1:** JOSHUA DAWSON HOUSE
- **STREET 2:** DAWSON STREET
- **CITY:** DUBLIN 2
- **STATE:** L2
- **ZIP:** D02 RY95

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 6-K

#### REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025.

#### Commission File Number: 001-40530

## GH Research PLC

#### (Exact name of registrant as specified in its charter)

#### Joshua Dawson House

#### Dawson Street

#### Dublin 2

#### D02 RY95

#### Ireland

#### (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F <u>☒</u> Form 40-F <u><br> </u>

------

GH Research PLC announces the presentation of data from its GH001-TRD-201 clinical trial at the 38<sup>th</sup> European College of Neuropsychopharmacology (ECNP) annual meeting, which is scheduled to take place from October 11-14, 2025, in Amsterdam, the Netherlands.

A copy of the poster to be presented by Dr. Fabian Devlin during Poster Session 3 on October 13, 2025, is attached hereto as Exhibit 99.1.

A copy of the poster to be presented by Prof. Bernhard T. Baune during Poster Session 4 on October 14, 2025, is attached hereto as Exhibit 99.2.

------

#### EXHIBIT INDEX

---

| | |
|:---|:---|
| [99.1](ef20056725_ex99-1.htm) | Poster to be presented by Dr. Fabian Devlin with Title: Psychoactive Effects of GH001 in Patients With Treatment-Resistant Depression: Results From a Phase 2b, Double-Blind, Randomised Controlled Trial |
| [99.2](ef20056725_ex99-2.htm) | Poster to be presented by Prof. Bernhard T. Baune with Title: Safety and Tolerability Results From a Phase 2b, Double-Blind Trial With an Open-Label Extension of GH001 in Treatment-Resistant Depression |

---

------

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **GH Research PLC** | **GH Research PLC** |
| Date: October 10, 2025 |  |  |
|  | By: | /s/ Julie Ryan |
|  | Name: | Julie Ryan |
|  | Title: | Vice President, Finance |

---

3<br>

------

## Exhibit 99.1

------

**Exhibit 99.1**<br>

![](devlin.jpg)

------

## Exhibit 99.2

------

**Exhibit 99.2**<br>

![](safety.jpg)

------